Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)

被引:479
作者
Panebianco, Valeria [1 ]
Narumi, Yoshifumi [2 ]
Altun, Ersan [3 ]
Bochner, Bernard H. [4 ]
Efstathiou, Jason A. [5 ]
Hafeez, Shaista [6 ,7 ]
Huddart, Robert [6 ,7 ]
Kennish, Steve [8 ]
Lerner, Seth [9 ]
Montironi, Rodolfo [10 ]
Muglia, Valdair F. [11 ]
Salomon, Georg [12 ]
Thomas, Stephen [13 ]
Vargas, Hebert Alberto [14 ]
Witjes, J. Alfred [15 ]
Takeuchi, Mitsuru [16 ]
Barentsz, Jelle [17 ]
Catto, James W. F. [18 ]
机构
[1] Sapienza Univ Rome, Dept Radiol Sci Oncol & Pathol, Rome, Italy
[2] Osaka Med Coll, Dept Radiol, Takatsuki, Osaka, Japan
[3] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA
[6] Inst Canc Res, Sutton, Surrey, England
[7] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[8] Sheffield Teaching Hosp NHS Trust, Dept Radiol, Sheffield, S Yorkshire, England
[9] Baylor Coll Med, Scott Dept Urol, Houston, TX USA
[10] Polytech Univ Marche Reg, United Hosp, Sch Med, Sect Pathol Anat, Ancona, Italy
[11] Univ Sao Paulo, Ribeirao Preto Med Sch, Imaging Div, Ribeirao Preto, Brazil
[12] Univ Clin Hamburg Eppendorf, Martini Clin, Hamburg, Germany
[13] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA
[14] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA
[15] Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands
[16] Radiolonet Tokai, Dept Radiol, Nagoya, Aichi, Japan
[17] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, Nijmegen, Netherlands
[18] Univ Sheffield, Acad Urol Unit, Sheffield, S Yorkshire, England
关键词
Bladder cancer; Multiparametric magnetic resonance imaging; Scoring; Staging; RADS; TRANSITIONAL-CELL CARCINOMA; INVASIVE UROTHELIAL CARCINOMA; LONG-TERM OUTCOMES; COMBINED-MODALITY THERAPY; DIFFUSION-WEIGHTED-MRI; CONTRAST-ENHANCED MRI; RADICAL CYSTECTOMY; NEOADJUVANT CHEMOTHERAPY; HIGH-RISK; STAGE-TA;
D O I
10.1016/j.eururo.2018.04.029
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: Management of bladder cancer (BC) is primarily driven by stage, grade, and biological potential. Knowledge of each is derived using clinical, histopathological, and radiological investigations. This multimodal approach reduces the risk of error from one particular test, but may present a staging dilemma when results conflict. Multiparametric magnetic resonance imaging (mpMRI) may improve patient care through imaging of the bladder with better resolution of the tissue planes than computed tomography and without radiation exposure. Objective: To define a standardized approach to imaging and reporting mpMRI for BC, by developing a VI-RADS score. Evidence acquisition: We created VI-RADS (Vesical Imaging-Reporting And Data System) through consensus using existing literature. Evidence synthesis: We describe standard imaging protocols and reporting criteria (including size, location, multiplicity, and morphology) for bladder mpMRI. We propose a five-point VI-RADS score, derived using T2-weighted MRI, diffusion-weighted imaging, and dynamic contrast enhancement, which suggests the risks of muscle invasion. We include sample images used to understand VI-RADS. Conclusions: We hope that VI-RADS will standardize reporting, facilitate comparisons between patients, and in future years, will be tested and refined if necessary. While we do not advocate mpMRI for all patients with BC, this imaging may compliment pathology or reduce radiation-based imaging. Bladder mpMRI may be most useful in patients with non-muscle-invasive cancers, in expediting radical treatment or for determining response to bladder-sparing approaches. Patient summary: Magnetic resonance imaging (MRI) scans for bladder cancer are becoming more common and may provide accurate information that helps improve patient care. Here, we describe a standardized reporting criterion for bladder MRI. This should improve communication between doctors and allow better comparisons between patients. (C) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:294 / 306
页数:13
相关论文
共 87 条
[21]   Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients [J].
Gontero, Paolo ;
Sylvester, Richard ;
Pisano, Francesca ;
Joniau, Steven ;
Eeckt, Kathy Vander ;
Serretta, Vincenzo ;
Larre, Stephane ;
Di Stasi, Savino ;
Van Rhijn, Bas ;
Witjes, Alfred J. ;
Grotenhuis, Anne J. ;
Kiemeney, Lambertus A. ;
Colombo, Renzo ;
Briganti, Alberto ;
Babjuk, Marek ;
Malmstrom, Per-Uno ;
Oderda, Marco ;
Irani, Jacques ;
Malats, Nuria ;
Baniel, Jack ;
Mano, Roy ;
Cai, Tommaso ;
Cha, Eugene K. ;
Ardelt, Peter ;
Varkarakis, John ;
Bartoletti, Riccardo ;
Spahn, Martin ;
Johansson, Robert ;
Frea, Bruno ;
Soukup, Viktor ;
Xylinas, Evanguelos ;
Dalbagni, Guido ;
Karnes, R. Jeffrey ;
Shariat, Shahrokh F. ;
Palou, Joan .
EUROPEAN UROLOGY, 2015, 67 (01) :74-82
[22]   Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use [J].
Gordon, Patrick C. ;
Thomas, Francis ;
Noon, Aidan P. ;
Rosario, Derek J. ;
Catto, James W. F. .
EUROPEAN UROLOGY FOCUS, 2019, 5 (04) :650-657
[23]   Mortality Increases When Radical Cystectomy Is Delayed More Than 12 Weeks Results From a Surveillance, Epidemiology, and End Results-Medicare Analysis [J].
Gore, John L. ;
Lai, Julie ;
Setodji, Claude M. ;
Litwin, Mark S. ;
Saigal, Christopher S. .
CANCER, 2009, 115 (05) :988-996
[24]   International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial [J].
Griffiths, Gareth .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2171-2177
[25]   Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J].
Grossman, HB ;
Natale, RB ;
Tangen, CM ;
Speights, VO ;
Vogelzang, NJ ;
Trump, DL ;
White, RWD ;
Sarosdy, MF ;
Wood, DP ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :859-866
[26]   Use of diffusion weighted-MRI (DW-MRI) as a prognostic biomarker of survival and time to cystectomy in muscle invasive bladder cancer (MIBC) following organ conserving treatment [J].
Hafeez, S. ;
Koh, M. D. ;
Sohaib, A. ;
Huddart, R. .
EUROPEAN JOURNAL OF CANCER, 2017, 72 :S192-S192
[27]   Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder [J].
Hafeez, S. ;
Horwich, A. ;
Omar, O. ;
Mohammed, K. ;
Thompson, A. ;
Kumar, P. ;
Khoo, V. ;
Van As, N. ;
Eeles, R. ;
Dearnaley, D. ;
Huddart, R. .
BRITISH JOURNAL OF CANCER, 2015, 112 (10) :1626-1635
[28]  
HAFEEZ S, 2013, RADIOTHER ONCOL S2, V106, pS180, DOI DOI 10.1016/S0167-8140(15)32770-5.0
[29]   Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update [J].
Hall, M. Craig ;
Chang, Sam S. ;
Dalbagni, Guido ;
Pruthi, Raj Som ;
Seigne, John Derek ;
Skinner, Eila Curlee ;
Wolf, J. Stuart, Jr. ;
Schellhammer, Paul F. .
JOURNAL OF UROLOGY, 2007, 178 (06) :2314-2330
[30]   A new staging criterion for bladder carcinoma using gadolinium-enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography [J].
Hayashi, N ;
Tochigi, H ;
Shiraishi, T ;
Takeda, K ;
Kawamura, J .
BJU INTERNATIONAL, 2000, 85 (01) :32-36